Metrics as of 10/16/2026, 07:59 PM (Berlin time), refresh in progress.
Denali Therapeutics Stock
Denali Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ryan J. Watts
- Employees
- 503
- Market cap
- $2.8 B
- IPO
- 08/12/2017
Denali Therapeutics Inc. is a biopharmaceutical firm in the healthcare sector based in South San Francisco, USA. Founded in 2013, the company focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company went public on December 8, 2017, and is currently led by…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Denali Therapeutics stock: price history
1D
-5.0%
1W
-10.4%
1M
-13.1%
6M
-15.3%
YTD
+5.6%
1Y
+4.2%
2Y
-37.0%
5Y
-61.7%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~33% stronger price swings than usual
Ask the agents about Denali Therapeutics
Analyst assessment of Denali Therapeutics
PRICE TARGET LOW
US$26.00
CONSENSUS
US$33.67
MEDIAN
US$34.00
PRICE TARGET HIGH
US$41.00
0
STRONG BUY
19
BUY
0
HOLD
0
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 25/08/2026
Denali Therapeutics stock metrics
P/E
-6.14
P/B
3.91
EV/EBITDA
-5.24
RETURN ON EQUITY
-15.3%
NET MARGIN
-3,539.2%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.7%
FLOAT SHARES
149,709,184
AVG. DAILY VOLUME (30D)
1,818,696
Insider transactions (SEC)
Chin Peter Scott
Thornberry Nancy
Thornberry Nancy
Schuth Alexander O.
Watts Ryan J.
Institutional holders
Comparable stocks
Frequently asked questions about Denali Therapeutics stock
What does Denali Therapeutics do?
Denali Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ryan J. Watts, the company employs around 503 people.
The IPO was on 08/12/2017; the stock trades on NASDAQ under the ticker DNLI.
What do analysts say about Denali Therapeutics stock?
19 analysts rate the stock, the consensus is Buy (as of 25/08/2026).
The average price target is US$33.67, ranging from US$26.00 to US$41.00, with a median of US$34.00.
This is an external assessment, not a statement by Market Jury.
When does Denali Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 33% stronger than usual.
Does Denali Therapeutics pay a dividend?
No, Denali Therapeutics currently does not pay a dividend.
Which stocks are comparable to Denali Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Denali Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Denali Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.